



Supplementary Figure 17. First round of screening of newly developed monoclonal antibody and dimeric nanobody reagent pairs in patient plasma. Affinity reagent pairs selected from initial screening with recombinant ORF1 protein (Supplementary Figure 8) were screened in small sets of plasma samples from healthy and cancer (colorectal and gastroesophageal) patients. Eight healthy and eight cancer patients were used in each set of assays in (A) and (B). Blue dashed lines indicate assay limits of detection, accounting for four-fold dilution. Each assay is denoted by the capture/detector reagent pair. The first-generation assay (Nb5/Ab6) measurements are depicted for comparison (gray box).